|
IGA Glomerulonephritis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that potential genetic interactions of C1GALT1 and ST6GALNAC2 variants influence IgA1 O-glycosylation, disease predisposition, and disease severity, and may contribute to the polygenic nature of IgAN.
|
19357720 |
2009 |
|
IGA Glomerulonephritis
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Expression of ST6GALNAC2 in B peripheral lymphocytes was significantly lower in patients with IgAN than that in normal controls (3.7 +/- 2.2 versus 6.3 +/- 2.3, P = 0.016); alpha2,6-ST activity in B lymphocytes was correlated positively with the level of alpha2,6-sialic acid in serum IgA1 in patients (n = 42) and controls (n = 12) (r = 0.37, P = 0.007).
|
19170967 |
2009 |
|
IGA Glomerulonephritis
|
0.330 |
Biomarker
|
disease |
CTD_human |
Our results demonstrated that the frequency of haplotype ADG in the promoter region of ST6GALNAC2 was significantly higher in IgAN patients than that in controls (p=0.0069; odds ratio [OR]=1.36; 95% confidence interval [CI], 1.08-1.72).
|
17480010 |
2007 |
|
IGA Glomerulonephritis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrated that the frequency of haplotype ADG in the promoter region of ST6GALNAC2 was significantly higher in IgAN patients than that in controls (p=0.0069; odds ratio [OR]=1.36; 95% confidence interval [CI], 1.08-1.72).
|
17480010 |
2007 |
|
Serum albumin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
A genome-wide assessment of variability in human serum metabolism.
|
23281178 |
2013 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The present study investigated the alteration in expression of ST6GalNAcII involved in invasion and to clarify the possible mechanism of ST6GalNAcII in the metastasis process in human follicular thyroid carcinoma cell lines.
|
26820593 |
2016 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Aggressive estrogen receptor-negative breast cancers with reduced ST6GalNAc2 expression alter O-linked glycans on tumor cell surface, increasing soluble lectin galectin-3 binding and tumor cell clustering at metastatic sites.
|
24596201 |
2014 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
ST6GalNAcII elucidated the unusual properties of invasion in breast cancer cell via modulating the PI3K/AKt signaling pathway.
|
24756995 |
2014 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The objective of this study is to clarify the possible role and mechanism of ST6GalNAcII in the metastasis process of breast carcinoma.
|
24756995 |
2014 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In this issue of Cancer Discovery, Murugaesu and colleagues, using an in vivo functional RNA interference metastasis screen, identified sialyltransferase ST6GalNAc2 as a novel metastasis suppressor gene.
|
24596201 |
2014 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Using this approach, we identified the sialyltransferase ST6GalNAc2 as a novel breast cancer metastasis suppressor.
|
24520024 |
2014 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
The SIATL1 gene, encoding STM, was mapped to the long arm of human chromosome 17 at q23-qter, a region that is nonrandomly deleted in human breast cancers.
|
11984005 |
2002 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We measured the levels of miR-182, miR-135b, and ST6GALNAC2 in a series of CRC cell lines and tissues using real-time PCR.
|
29030743 |
2017 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Suppression of these miRNAs implicated an inverse function, while altered expression of ST6GALNAC2 mediated CRC progression upon transfection with miR-135b/-182 mimic or inhibitor.
|
28767179 |
2017 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In particular, we observed an enrichment of mutations in genes (B3GNT2, B4GALT2, ST6GALNAC2) involved in the biosynthesis of N- and Cores 1-3 O-linked glycans in the colon, accounting for ~16% of the CRCs tested.
|
27004849 |
2016 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Sticking to sugars at the metastatic site: sialyltransferase ST6GalNAc2 acts as a breast cancer metastasis suppressor.
|
24596201 |
2014 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
ST6GalNAcII elucidated the unusual properties of invasion in breast cancer cell via modulating the PI3K/AKt signaling pathway.
|
24756995 |
2014 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, taken together, our results imply that ST6GalNAcII activated the invasion in follicular thyroid cancer cells through regulating the activity of PI3K/Akt pathway.
|
26820593 |
2016 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors.
|
24520024 |
2014 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Aggressive estrogen receptor-negative breast cancers with reduced ST6GalNAc2 expression alter O-linked glycans on tumor cell surface, increasing soluble lectin galectin-3 binding and tumor cell clustering at metastatic sites.
|
24596201 |
2014 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
ST6GalNAcII elucidated the unusual properties of invasion in breast cancer cell via modulating the PI3K/AKt signaling pathway.
|
24756995 |
2014 |
|
Major Depressive Disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the expression of ST6GALNAC2 was decreased in leukocytes from patients with MDD.
|
28844310 |
2018 |
|
Tumor Angiogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, miR-182/-135b inhibited significantly ST6GALNAC2 expression, and consistently, ST6GALNAC2 mediated migration, adhesion, invasion, proliferation, and tumor angiogenesis in CRC cell lines.
|
29030743 |
2017 |